 Global Blood Therapeutics Inc NASDAQ: GBT has announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study evaluating Oxbryta voxelotor tablets in patients with sickle cell disease SCD. The results showed a significant and sustained improvement in hemoglobin levels, reduction in hemolysis, and improved overall health status, thus supporting the long-term use of Oxbryta. 